Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $1.70 Million Stock Holdings in Pfizer Inc. $PFE

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 32.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,102 shares of the biopharmaceutical company’s stock after selling 31,348 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Pfizer were worth $1,699,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Horizon Financial Services LLC increased its holdings in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the last quarter. YANKCOM Partnership acquired a new position in shares of Pfizer during the 4th quarter worth $28,000. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter valued at $29,000. Darwin Wealth Management LLC bought a new stake in Pfizer in the second quarter worth $32,000. Finally, True Wealth Design LLC increased its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on PFE shares. Bank of America cut their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. UBS Group boosted their price objective on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. Guggenheim raised their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.48.

Pfizer Stock Down 1.9%

Shares of PFE opened at $26.78 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average price of $27.26 and a two-hundred day moving average price of $26.05. The stock has a market cap of $152.28 billion, a price-to-earnings ratio of 19.69 and a beta of 0.43. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $0.63 EPS. Equities analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; record/ex?div May 8), the 350th consecutive quarterly payout — supports income investors and signals cash?flow confidence. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Pfizer’s GLP?1 weight?management drug Xianweiying is available for pre?order in China — early commercialization there could materially expand revenue opportunity versus peers. Pfizer GLP-1 weight loss drug available for pre-order in China
• Positive Sentiment: Company to present broad oncology pipeline data at ASCO (multiple abstracts, late?breaking sessions) — positive for long?term growth if trial readouts show benefit. Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
• Neutral Sentiment: Analysts maintain mixed views — the consensus rating is “Hold,” reflecting cautious expectations despite recent execution. Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts
• Neutral Sentiment: Preview pieces note Pfizer’s history of modest earnings beats and margin improvement from cost cuts — upcoming results could surprise but uncertainties (patent cliffs, product mix) remain. Pfizer Could Surprise Again This Earnings Season (Preview)
• Negative Sentiment: Barclays reiterated a “Sell” — a high?profile sell rating increases downward pressure on sentiment and trading. Barclays Remains a Sell on Pfizer (PFE)
• Negative Sentiment: Royal Bank of Canada assigned an Underperform — another downgrade that can pressure the share price and reduce buy?side conviction. Pfizer (NYSE:PFE) Earns Underperform Rating from Royal Bank Of Canada
• Negative Sentiment: Top strategy executive is leaving — leadership turnover creates short?term execution risk and may add to investor caution. Pfizer’s top strategy executive is leaving

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.